KI
SMMT icon

Kapitalo Investimentos’s Summit Therapeutics SMMT Stock Holding History

Kapitalo Investimentos’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-57,200
Closed -$243K – 496
2022
Q4 		$243K Buy
+57,200
New +$104K 0.18% 30

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return

Kapitalo Investimentos's SMMT Position: Q1 2023 in Review

Kapitalo Investimentos sold out of Summit Therapeutics (SMMT) in Q1 2023, closing a stake of 57,200 shares — an estimated $243K sold.

Kapitalo Investimentos first reported a position in SMMT in Q4 2022 and held it in 1 quarter. The position peaked at $243K in Q4 2022. 91 funds tracked by Wall St. Rank hold SMMT as of Q1 2023.

  • Kapitalo Investimentos reported no remaining Summit Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Kapitalo Investimentos sold 57,200 Summit Therapeutics shares in Q1 2023, an estimated $243K.
  • Kapitalo Investimentos first reported a position in Summit Therapeutics in Q4 2022 and held it in 1 quarter.
  • Kapitalo Investimentos's Summit Therapeutics position peaked at $243K in Q4 2022.
  • 91 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2023.

Based on Kapitalo Investimentos's 13F filing for Q1 2023, filed 29 Mar 2024.